CA2311456A1 - Imidazonaphthyridines and their use in inducing cytokine biosynthesis - Google Patents

Imidazonaphthyridines and their use in inducing cytokine biosynthesis Download PDF

Info

Publication number
CA2311456A1
CA2311456A1 CA002311456A CA2311456A CA2311456A1 CA 2311456 A1 CA2311456 A1 CA 2311456A1 CA 002311456 A CA002311456 A CA 002311456A CA 2311456 A CA2311456 A CA 2311456A CA 2311456 A1 CA2311456 A1 CA 2311456A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002311456A
Other languages
French (fr)
Other versions
CA2311456C (en
Inventor
Kyle J. Lindstrom
John F. Gerster
Stephen L. Crooks
Philip D. Heppner
Gregory J. Marszalek
Peter V. Maye
Bryon A. Merrill
John W. Mickelson
Michael J. Rice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2311456A1 publication Critical patent/CA2311456A1/en
Application granted granted Critical
Publication of CA2311456C publication Critical patent/CA2311456C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

Imidazonaphthyridine (I) and tetrahydroimidazonaphthyridine (II) compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed. R1 and R2 and A
are as defined in the application.

Claims (26)

1. A compound of the formula I:

wherein A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;
R1 is selected from the group consisting of:
- hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-N3;
oxo;
-halogen;

-NO2;
-OH; and -SH; and -C1-20 alkyl-NR3-Q-X-R4 or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisiting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2 -NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;
R2 is selected from the group consisting of:
-hydrogen;
-C1-10 alkyl;
-C2-20 alkenyl;
-aryl;
-C1-10 alkyl -O-C1-10-alkyl;
-C1-10 alkyl-O-C2-10alkenyl; and -C1-10 alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
each R3 is independently selected from the group consisting of hydrogen and C1-alkyl; and each R is independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1 wherein R1 is selected from the group consisting of C1-6 alkyl and C1-6 hydroxyalkyl.
3. A compound according to Claim 2 wherein R1 is selected from the group consisting of n-butyl, 2-hydroxy-2-methylpropyl, and 2-methylpropyl.
4. A compound according to Claim 1 wherein R2 is selected from the group consisting of C1-6 straight chain alkyl and alkoxyalkyl wherein the alkoxy moiety and the alkyl moiety each independently contain 1 to 4 carbon atoms.
5. A compound according to Claim 4 wherein R2 is selected from the group consisting of methyl, n-butyl, benzyl, ethoxymethyl, and methoxyethyl.
6. A compound according to Claim 1 wherein each R is hydrogen.
7. A compound according to Claim 1 wherein R1 is -C1-20 alkyl-NR3-Q-X-R4.
8. A compound according to Claim 7 wherein R4 is
9. A compound according to Claim 1 wherein A is =CH-CH=CH-N=.
10. A compound of the formula II:

wherein B is -NR-C(R)2-C(R)2-C(R)2-; -C(R)2-NR-C(R)2-C(R)2-;
-C(R)2-C(R)2-NR-C(R)2- or -C(R)2-C(R)2-C(R)2-NR-;
R1 is selected from the group consisting of:
- hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; and -C1-20 alkyl-NR3-Q-X-R4 or -C2-20 alkenyl-NR3-CO-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;

R1 is selected from the group consisting of:
-hydrogen;
-C1-10 alkyl;
-C2-10 alkenyl;
-aryl;
-C1-10 alkyl -O-C1-10-alkyl;
-C1-10 alkyl-O-C2-10 alkenyl; and -C1-10 alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
each R3 is independently selected from the group consisting of hydrogen and C1-alkyl; and each R is independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
11. A compound according to Claim 10 wherein R1 is selected from the group consisting of C1-6 alkyl and C1-6 hydroxyalkyl.
12. A compound according to Claim 11 wherein R1 is selected from the group consisting of n-butyl, 2-hydroxy-2-methylpropyl, and 2-methylpropyl.
13. A compound according to Claim 10 wherein R2 is selected from the group consisting of methyl, n-butyl, benzyl, ethoxymethyl, and methoxyethyl.
14. A compound according to Claim 10 wherein each R is hydrogen.
15. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 10 and a pharmaceutically acceptable carrier.
17. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound according to Claim 1 to the animal.
18. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound according to Claim 10 to the animal.
19. A method of treating a viral infection in an animal comprising admistering an effective amount of a compound according to claim 1 to the animal.
20. A method of treating a viral infection man animal comprising administering an effective amount of a compounds according to claim 10 to the aminal.
21. A compound of formula wherein A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;
R1 is selected from the group consisting of:

- hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(RO3)2;
-N>;
oxo;
-halogen;

-OH; and -SH; and -C1-20 alkyl-NR3-Q-X-R4, or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;

-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;
R2 is selected from the group consisting of:
-hydrogen;
-C1-10 alkyl;
-C2-10 alkenyl;
-aryl -C1-10 alkyl -O-C1-10-alkyl;
-C1-10 alkyl-O-C2-10, alkenyl; and -C1-10 alkyl or C2-10, alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;

-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
each R3 is independently selected from the group consisting of hydrogen and C1-alkyl; and each R is independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
22. A compound of formula wherein R1 is selected from the group consisting of:
- hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;

-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; and -C1-20 alkyl-NR3-Q-X-R4, or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20, alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consiting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2, -NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;
R2 is selected from the group consisting of:
-hydrogen;
-C1-10 alkyl;
-C2-10 alkenyl;
-aryl;
-C1-10 alkyl -O-C1-10-alkyl;
-C1-10 alkyl-O-C2-10 alkenyl; and -C1-10 alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consiting of:
-OH;
-halogen;
-N(R3)2 -CO-N(R3)2;
-CO-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
each R3 is independently selected from the group consisting of hydrogen and C1-alkyl; and each R is independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
23. A compound of formula wherein R1 is selected from the group consisting of:
- hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2 -C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;

-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH;
-C1-20 alkyl-NR3-Q-X-R4 or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;
R2 is selected from the group consisting of:
-hydrogen;
-C1-10 alkyl;
-C2-10 alkenyl;
-aryl;
-C1-10 alkyl -O-C1-10-alkyl;
-C1-10 alkyl-O-C2-10 alkenyl; and -C1-10 alkyl or C2-10 alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen;
-N(R3)2;
-CO-N(R3)2;
-CO-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
each R3 is independently selected from the group consisting of hydrogen and C1-alkyl; and each R is independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.
24. A compound of Formula wherein A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;
R7 is OH, halogen, or NHR1, R1 is selected from the group consisting of:
- hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)02-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-N3;
oxo;
-halogen;
-NO2;

-OH; and -SH; and -C1-20 alkyl-NR3-Q-X-R4 or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl, -O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2:
-NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;
R8 is H, NO2 or NH2; and each R is independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
25. A compound of formula wherein A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N= and R9 is H or C1-10 alkyl.
26. A compound of formula wherein R1 is selected from the group consisting of:
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl;

-O-(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;
-N3;
oxo;
-halogen;

-OH; and -SH;
-C1-20 alkyl-NR3-Q-X-R4 or -C2-20 alkenyl-NR3-Q-X-R4 wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR3- and R4 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20o alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-C1-20 alkyl;
-O(C1-20alkyl)0-1-aryl;
-O-(C1-20alkyl)0-1-heteroaryl;
-O-(C1-20alkyl)0-1-heterocyclyl;
-C1-20 alkoxycarbonyl;
-S(O)0-2-C1-20 alkyl;
-S(O)0-2-(C1-20 alkyl)0-1-aryl;
-S(O)0-2-(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2-(C1-20 alkyl)0-1-heterocyclyl;
-N(R3)2;

-NR3-CO-O-C1-20alkyl;
-N3;
oxo;
-halogen;
-NO2;
-OH; and -SH; or R4 is wherein Y is -N- or -CR-;
each R3 is independently selected from the group consisting of hydrogen and C1-alkyl;
each R is selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl; and R10 is -NO2 or NH2;
or a pharmaceutically acceptable salt thereof.
CA2311456A 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis Expired - Lifetime CA2311456C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6927697P 1997-12-11 1997-12-11
US60/069,276 1997-12-11
PCT/US1998/026473 WO1999029693A1 (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis

Publications (2)

Publication Number Publication Date
CA2311456A1 true CA2311456A1 (en) 1999-06-17
CA2311456C CA2311456C (en) 2010-11-02

Family

ID=22087889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2311456A Expired - Lifetime CA2311456C (en) 1997-12-11 1998-12-11 Imidazonaphthyridines and their use in inducing cytokine biosynthesis

Country Status (28)

Country Link
US (14) US6194425B1 (en)
EP (1) EP1040112B1 (en)
JP (4) JP4283438B2 (en)
KR (3) KR100642702B1 (en)
CN (1) CN1154647C (en)
AT (3) ATE333456T1 (en)
AU (1) AU753864B2 (en)
BR (1) BR9814275A (en)
CA (1) CA2311456C (en)
CZ (1) CZ307184B6 (en)
DE (3) DE69835844T2 (en)
DK (1) DK1512686T3 (en)
EE (1) EE04314B1 (en)
ES (3) ES2270249T3 (en)
HK (1) HK1070655A1 (en)
HR (1) HRP20000363B1 (en)
HU (1) HUP0101155A3 (en)
IL (4) IL136556A0 (en)
NO (3) NO316687B1 (en)
NZ (1) NZ504776A (en)
PL (1) PL193915B1 (en)
PT (3) PT1512686E (en)
RU (3) RU2312867C2 (en)
SI (1) SI1512686T1 (en)
SK (2) SK286304B6 (en)
TR (1) TR200001705T2 (en)
UA (1) UA67760C2 (en)
WO (1) WO1999029693A1 (en)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CA2361936C (en) 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1198233T1 (en) * 1999-06-10 2007-02-28 3M Innovative Properties Co Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
EP1438958A1 (en) * 1999-06-10 2004-07-21 3M Innovative Properties Company Carbamate substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20040209877A1 (en) * 2000-04-13 2004-10-21 Shelby Nancy J. Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US20020110840A1 (en) * 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005501550A (en) * 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー Maturation of plasmacytoid dendritic cells using immune response modifier molecules
DE60230340D1 (en) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2541132T3 (en) * 2002-02-22 2015-07-16 Meda Ab Method to reduce and treat UV-B-induced immunosuppression
MXPA04012199A (en) * 2002-06-07 2005-02-25 3M Innovative Properties Co Ether substituted imidazopyridines.
EP1545597B1 (en) 2002-08-15 2010-11-17 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AU2003299082A1 (en) * 2002-09-26 2004-04-19 3M Innovative Properties Company 1h-imidazo dimers
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004058759A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CA2511538C (en) * 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
CA2517528A1 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
EP1605943A4 (en) * 2003-03-07 2008-01-16 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US20040202720A1 (en) * 2003-04-10 2004-10-14 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20040214851A1 (en) * 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
AR044466A1 (en) * 2003-06-06 2005-09-14 3M Innovative Properties Co PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
CA2534042A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Compositions for encapsulation and controlled release
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
TW200510412A (en) * 2003-08-12 2005-03-16 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
CA2535338C (en) * 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
ES2545826T3 (en) * 2003-08-14 2015-09-16 3M Innovative Properties Company Lipid Modified Immune Response Modifiers
US8961477B2 (en) * 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007504145A (en) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Immunostimulatory combinations and treatments
CA2536136C (en) * 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504172A (en) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Methods for treatment of mucosa related symptoms
JP2007504269A (en) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
WO2005033049A2 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
JP5043435B2 (en) * 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー Alkoxy substituted imidazoquinolines
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CN1906193A (en) * 2003-11-14 2007-01-31 3M创新有限公司 Oxime substituted imidazo ring compounds
AU2004291122A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1686992A4 (en) * 2003-11-25 2009-11-04 3M Innovative Properties Co Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AR046781A1 (en) 2003-11-25 2005-12-21 3M Innovative Properties Co IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS.
EP1689361A4 (en) * 2003-12-02 2009-06-17 3M Innovative Properties Co Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005076783A2 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2552101A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
WO2005066169A2 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005222995B2 (en) * 2004-03-15 2010-08-26 3M Innovative Properties Company Immune response modifier formulations and methods
WO2005094531A2 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co Methods, compositions, and preparations for delivery of immune response modifiers
JP2008505857A (en) * 2004-04-28 2008-02-28 スリーエム イノベイティブ プロパティズ カンパニー Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
AU2005282523A1 (en) * 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
AU2005282726B2 (en) * 2004-09-02 2011-06-02 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
JP2008515928A (en) * 2004-10-08 2008-05-15 スリーエム イノベイティブ プロパティズ カンパニー Adjuvants for DNA vaccines
EP1833836B1 (en) 2004-11-12 2011-12-21 Bristol-Myers Squibb Company Imidazo-fused thiazolo [4,5-b] pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2006053166A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP2008526765A (en) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー Treatment of skin metastases
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
EP1853594A2 (en) 2005-01-27 2007-11-14 Alma Mater Studiorum -Universita' di Bologna Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2006084251A2 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530113A (en) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド Oxime and hydroxyramine substituted imidazo [4,5-c] ring compounds and methods
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
US8178677B2 (en) * 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008531567A (en) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド Hydroxyalkyl-substituted imidazoquinoline compounds and methods
AU2006216799A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
MX2007011112A (en) * 2005-03-14 2007-11-07 Graceway Pharmaceuticals Llc Method of treating actinic keratosis.
CA2602853A1 (en) 2005-04-01 2006-11-16 Coley Pharmaceutical Group, Inc. Ring closing and related methods and intermediates
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (en) 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー Immune activation composition
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
EA200800782A1 (en) * 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. AMIDA AND CARBAMATE DERIVATIVES N- {2- [4-AMINO-2- (ETOXIMETHYL) -1H-IMIDAZOLO [4,5-c] QUINOLIN-1-IL] -1,1-DIMETHYLETHYL} METHANE SULFONAMIDE AND METHODS
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
JP5247458B2 (en) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007079086A1 (en) * 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007143526A2 (en) * 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
NO343857B1 (en) * 2006-07-18 2019-06-24 Meda Ab Immune Response Modifying Foam Formulations
US8124096B2 (en) * 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
EP2121023A1 (en) * 2006-12-22 2009-11-25 3M Innovative Properties Company Controlled release composition and process
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20090018155A1 (en) * 2007-02-08 2009-01-15 Gregory Jefferson J Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110021555A1 (en) 2008-12-19 2011-01-27 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses
CA3033133C (en) 2009-03-25 2021-11-09 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
TW201100424A (en) * 2009-03-31 2011-01-01 Arqule Inc Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
US8511006B2 (en) * 2009-07-02 2013-08-20 Owens Corning Intellectual Capital, Llc Building-integrated solar-panel roof element systems
US20110207766A1 (en) 2009-07-13 2011-08-25 Graceway Pharmaceuticals, Llc. Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
CN102712640A (en) * 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 Tricyclic heterocyclic compounds, compositions and methods of use thereof
CA2803339C (en) 2010-06-25 2023-06-13 Michael T. Nordsiek Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
JP6460789B2 (en) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker
BR112013031039B1 (en) 2011-06-03 2020-04-28 3M Innovative Properties Co hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013040447A2 (en) 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
DK2844282T3 (en) 2012-05-04 2019-07-15 Pfizer PROSTATA ASSOCIATED ANTIGENES AND VACCINE-BASED IMMUNTERAPIREGIMENES
CN112587658A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
MX2015008773A (en) 2013-01-07 2015-11-06 Univ Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma.
US9919029B2 (en) 2013-07-26 2018-03-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
CN105873587B (en) 2013-11-05 2020-07-21 3M创新有限公司 Sesame oil-based injection formulations
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
DK3166976T3 (en) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc ANTI-PD-L1 COMBINATIONS FOR TREATMENT OF TUMORS
CN105233291A (en) 2014-07-09 2016-01-13 博笛生物科技有限公司 Combined therapy composition and combined therapy method for treating cancers
CN112587672A (en) 2014-09-01 2021-04-02 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EP3298131B1 (en) 2015-05-20 2023-04-26 The Regents of The University of California Method for generating human dendritic cells for immunotherapy
WO2017040233A1 (en) 2015-08-31 2017-03-09 3M Innovative Properties Company GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
CN107922416B (en) * 2015-08-31 2021-07-02 3M创新有限公司 Imidazo [4,5-c ] ring compounds containing substituted guanidine groups
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN106943597A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti-EGFR for treating tumour is combined
CN115350279A (en) 2016-01-07 2022-11-18 博笛生物科技有限公司 anti-HER 2 combinations for the treatment of tumors
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
JP6883806B2 (en) * 2016-03-09 2021-06-09 国立大学法人大阪大学 Compounds and organic semiconductor materials containing them
JP7195147B2 (en) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート PEGylated liposomes and methods of use
KR102392974B1 (en) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Formulations containing TLR agonists and methods of use
EP3504215B1 (en) 2016-08-26 2022-04-06 3M Innovative Properties Company Fused [1,2]imidazo[4,5-c]ring compounds substituted with guanidino groups
KR102497742B1 (en) 2016-08-30 2023-02-10 다나-파버 캔서 인스티튜트 인크. Drug Delivery Compositions and Uses Thereof
CA3043480A1 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
CN110072519A (en) 2016-12-14 2019-07-30 普罗根尼蒂公司 Use JAK inhibitor for treating enterogastric diseases and device
EP3554540B1 (en) 2016-12-14 2023-08-02 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP2020513280A (en) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド Treatment of digestive tract diseases with immunosuppressants
WO2018160552A1 (en) 2017-03-01 2018-09-07 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
BR112019027025A2 (en) 2017-06-23 2020-06-30 Birdie Biopharmaceuticals, Inc. pharmaceutical compositions
WO2019040491A1 (en) 2017-08-22 2019-02-28 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereof
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CA3034912A1 (en) 2018-02-28 2019-08-28 Pfizer Inc. Il-15 variants and uses thereof
US11370788B2 (en) 2018-02-28 2022-06-28 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group
TWI793325B (en) 2018-05-23 2023-02-21 美商輝瑞大藥廠 Antibodies specific for cd3 and uses thereof
EP3796983A2 (en) 2018-05-23 2021-03-31 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
CN112218864B (en) 2018-05-24 2023-09-08 3M创新有限公司 N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions and methods
EP3887369A1 (en) 2018-11-26 2021-10-06 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN113924297A (en) 2019-06-06 2022-01-11 3M创新有限公司 N-1 branched alkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods
CN113906027A (en) 2019-06-12 2022-01-07 3M创新有限公司 Phenethyl substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
TW202216779A (en) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 Therapeutic antibodies and their uses

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3764681A (en) * 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ES2071340T3 (en) 1990-10-05 1995-06-16 Minnesota Mining & Mfg PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS.
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
JPH09500128A (en) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー Imidazo [4,5-c] pyridin-4-amine
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US6039969A (en) 1996-10-25 2000-03-21 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
PT839810E (en) * 1996-11-04 2003-01-31 Bayer Cropscience Sa 1-POLYARILPIRAZOIS AS PESTICIDES
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4101302B2 (en) 1997-01-09 2008-06-18 テルモ株式会社 Novel amide derivatives and synthetic intermediates
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CA2361936C (en) 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6545485B1 (en) * 1999-01-21 2003-04-08 Radar Engineers Ultrasonic pinpointer for power system sources of interference
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US20020110840A1 (en) * 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
WO2002102377A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
JP2005501550A (en) 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー Maturation of plasmacytoid dendritic cells using immune response modifier molecules
US6667347B2 (en) * 2001-09-14 2003-12-23 Chevron U.S.A. Inc. Scrubbing CO2 from methane-containing gases using an aqueous stream
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
DE60230340D1 (en) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2541132T3 (en) * 2002-02-22 2015-07-16 Meda Ab Method to reduce and treat UV-B-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003101949A2 (en) * 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
MXPA04012199A (en) * 2002-06-07 2005-02-25 3M Innovative Properties Co Ether substituted imidazopyridines.
EP1545597B1 (en) * 2002-08-15 2010-11-17 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AU2003299082A1 (en) * 2002-09-26 2004-04-19 3M Innovative Properties Company 1h-imidazo dimers
AU2003290988A1 (en) * 2002-11-14 2004-06-15 Pintex Pharmaceuticals, Inc. Levels of pin1 in normal and cancerous tissue
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004058759A1 (en) * 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CA2511538C (en) * 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
CA2517528A1 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
EP1605943A4 (en) * 2003-03-07 2008-01-16 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
AU2004220465A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
WO2004087049A2 (en) * 2003-03-25 2004-10-14 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040202720A1 (en) * 2003-04-10 2004-10-14 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040214851A1 (en) * 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
NZ545536A (en) * 2003-09-05 2010-04-30 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate

Also Published As

Publication number Publication date
UA67760C2 (en) 2004-07-15
US20020173654A1 (en) 2002-11-21
US20040006098A1 (en) 2004-01-08
US7678918B2 (en) 2010-03-16
US20030212093A1 (en) 2003-11-13
IL178092A (en) 2007-10-31
US20030096998A1 (en) 2003-05-22
DE69835309T2 (en) 2007-07-19
US20030083500A1 (en) 2003-05-01
JP2001525411A (en) 2001-12-11
RU2003126258A (en) 2005-03-10
US6949646B2 (en) 2005-09-27
ES2227902T3 (en) 2005-04-01
IL178091A (en) 2007-10-31
HUP0101155A3 (en) 2002-10-28
US20040023932A1 (en) 2004-02-05
NO20035718L (en) 2000-08-11
PL193915B1 (en) 2007-03-30
SI1512686T1 (en) 2007-02-28
HRP20000363A2 (en) 2001-06-30
RU2314307C2 (en) 2008-01-10
EE04314B1 (en) 2004-06-15
US20080091010A1 (en) 2008-04-17
US7038051B2 (en) 2006-05-02
DE69835309D1 (en) 2006-08-31
ES2273138T3 (en) 2007-05-01
JP4283438B2 (en) 2009-06-24
JP2007262093A (en) 2007-10-11
AU753864B2 (en) 2002-10-31
DE69835844T2 (en) 2007-04-19
IL136556A0 (en) 2001-06-14
US6797716B2 (en) 2004-09-28
CA2311456C (en) 2010-11-02
KR20040011532A (en) 2004-02-05
JP2008115190A (en) 2008-05-22
HUP0101155A2 (en) 2001-12-28
CN1154647C (en) 2004-06-23
DE69826518T2 (en) 2005-09-22
US6194425B1 (en) 2001-02-27
AU1912399A (en) 1999-06-28
CZ307184B6 (en) 2018-02-28
US6894165B2 (en) 2005-05-17
US6747040B2 (en) 2004-06-08
WO1999029693A1 (en) 1999-06-17
US7335773B2 (en) 2008-02-26
EP1040112B1 (en) 2004-09-22
SK285872B6 (en) 2007-10-04
NZ504776A (en) 2002-07-26
DK1512686T3 (en) 2007-01-15
CN1284957A (en) 2001-02-21
NO328045B1 (en) 2009-11-16
TR200001705T2 (en) 2001-07-23
RU2312867C2 (en) 2007-12-20
IL136556A (en) 2007-03-08
JP4203067B2 (en) 2008-12-24
NO20035719D0 (en) 2003-12-19
US6693113B2 (en) 2004-02-17
PL341159A1 (en) 2001-03-26
BR9814275A (en) 2000-10-03
NO20035718D0 (en) 2003-12-19
US6638944B2 (en) 2003-10-28
ATE277046T1 (en) 2004-10-15
EP1040112A1 (en) 2000-10-04
US6699878B2 (en) 2004-03-02
NO20002663D0 (en) 2000-05-24
US20060128674A1 (en) 2006-06-15
KR100563175B1 (en) 2006-03-27
CZ2007268A3 (en) 2016-09-29
HK1070655A1 (en) 2005-06-24
ATE333456T1 (en) 2006-08-15
NO316687B1 (en) 2004-04-05
US20050288320A1 (en) 2005-12-29
PT1512685E (en) 2006-12-29
KR20040011533A (en) 2004-02-05
PT1040112E (en) 2005-01-31
US20070167481A1 (en) 2007-07-19
WO1999029693A8 (en) 2004-11-04
KR100642702B1 (en) 2006-11-10
US6624172B2 (en) 2003-09-23
PT1512686E (en) 2007-01-31
DE69835844D1 (en) 2006-10-19
RU2003126259A (en) 2005-02-27
KR100642703B1 (en) 2006-11-10
NO20002663L (en) 2000-08-11
EE200000349A (en) 2001-10-15
ATE338757T1 (en) 2006-09-15
US6514985B1 (en) 2003-02-04
KR20010033016A (en) 2001-04-25
DE69826518D1 (en) 2004-10-28
US20050107421A1 (en) 2005-05-19
US20040204436A1 (en) 2004-10-14
RU2221798C2 (en) 2004-01-20
JP2006083188A (en) 2006-03-30
ES2270249T3 (en) 2007-04-01
HRP20000363B1 (en) 2005-06-30
SK8352000A3 (en) 2001-03-12
SK286304B6 (en) 2008-07-07

Similar Documents

Publication Publication Date Title
CA2311456A1 (en) Imidazonaphthyridines and their use in inducing cytokine biosynthesis
JP2001525411A5 (en)
CA2436980A1 (en) Amido ether substituted imidazoquinolines
RU2000114496A (en) IMIDAZONAPTHYRIDINE AND THEIR USE IN STIMULATING CYTOKINE BIOSYNTHESIS
CA2535338A1 (en) Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
RU92004336A (en) WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS
EA200400615A1 (en) AMIDOV DERIVATIVES AS AN INHIBITORS GLYOGENENSINTAZIN-KINAZ 3-BETA
CO5160348A1 (en) DERIVATIVES OF TIENO [2,3-D] PYRIMIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR950704320A (en) Pyrrolopyrimidine as a CRF antagonist (PYRROLOPYRIMIDINES AS CRF ANTAGONISTS)
EP2088141A3 (en) Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
JP2003501474A5 (en)
HUP0203548A2 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
EP0436653A1 (en) Synthesis of camptothecin and analogs thereof
RU2011133900A (en) CYCLOSPORIN ANALOGUES TO PREVENT OR TREAT HEPATITIS C INFECTION
EA200700144A1 (en) PYRIDOPYRIMIDINE DERIVATIVES, THEIR RECEIVING, THEIR APPLICATION IN THERAPY
RU2015104031A (en) SOME AMINOalkylGlucosamine-phosphate derivatives and their use
JP2009534358A5 (en)
AR065927A1 (en) DERIVATIVES OF 5,6-DIHIDRO-1H-PIRIDIN-2-ONA
RU2002132253A (en) 2-Acylindole derivatives, their use (options) and preparation method, medicament and preparation method, antitumor drug production and preparation thereof
RU2006146204A (en) 3-D-Ribofuranosylthiazole [4, 5-D] Pyrimidine Nucleosides and Their Applications
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
EP1475094B8 (en) Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
AU4555800A (en) Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
HUT47531A (en) Process for producing amide derivatives and pharmaceuticals comprising such compounds
WO1993016698A1 (en) SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181211